BiotechTube

PEG-somatropin

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Growth Hormone Deficiency

Conditions

Growth Hormone Deficiency

Trial Timeline

Mar 1, 2007 → Mar 1, 2008

NCT ID
NCT01495468

About PEG-somatropin

PEG-somatropin is a phase 3 stage product being developed by Sun Pharmaceutical for Growth Hormone Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT01495468. Target conditions include Growth Hormone Deficiency.

What happened to similar drugs?

11 of 20 similar drugs in Growth Hormone Deficiency were approved

Approved (11) Terminated (1) Active (9)
✅PEG-somatropinSun PharmaceuticalApproved
✅PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
✅Saizen® solution for injection (referred as Saizen®)MerckApproved
✅Saizen + SaizenMerckApproved
✅EverolimusNovartisApproved
✅somatropin + somatropin + somatropinNovo NordiskApproved
✅somatropin + placeboNovo NordiskApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03249480ApprovedUNKNOWN
NCT01495468Phase 3Completed

Competing Products

20 competing products in Growth Hormone Deficiency

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
40
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)Eli LillyPre-clinical
26
HER3-DXdDaiichi SankyoPre-clinical
26
ErlotinibAstellas PharmaPhase 2
27
radio-labeled naquotinib + naquotinibAstellas PharmaPhase 1
21
pegylated Somatropin + pegylated Somatropin + Jintropin AQSun PharmaceuticalPhase 2
35
PEG-somatropinSun PharmaceuticalApproved
39
PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
39
Somatropin + SomatropinEli LillyPhase 3
40
Somatropin + SomatropinEli LillyPhase 3
40
somatropin, rDNA origin, for injectionEli LillyPhase 3
40
Sterile becaplermin gel vs. sterile placebo gel treatment 1Johnson & JohnsonPre-clinical
26
ABT-414AbbViePre-clinical
26
Saizen® A + Saizen® BMerckPhase 3
40
Saizen® solution for injection (referred as Saizen®)MerckApproved
43
Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)MerckPhase 3
40
Saizen + SaizenMerckApproved
43
MiransertibMerckPhase 2
39
MiransertibMerckPhase 1/2
24
ARX201 + ARX201 + ARX201MerckPhase 2
35